



G-MDSC (CD15⁺CD33⁺CD11b⁺CD14⁻HLA-DR^{low}) gating

A




B

RGX-104 clinical trial patient 1 (pre-treatment)




RGX-104 clinical trial patient 1 (week 2 of treatment)




M-MDSC (CD14⁺Lin^{neg}HLA-DR^{low}) gating

C




Tumor MDSC

D



E



Activated T cells (GITR⁺CD8⁺CD3⁺) gating

F

